JP2017533912A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533912A5 JP2017533912A5 JP2017523273A JP2017523273A JP2017533912A5 JP 2017533912 A5 JP2017533912 A5 JP 2017533912A5 JP 2017523273 A JP2017523273 A JP 2017523273A JP 2017523273 A JP2017523273 A JP 2017523273A JP 2017533912 A5 JP2017533912 A5 JP 2017533912A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- cancer
- administered
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 35
- 229960003301 nivolumab Drugs 0.000 claims 13
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 12
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 12
- 201000002528 pancreatic cancer Diseases 0.000 claims 12
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 12
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 11
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 11
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 11
- 206010009944 Colon cancer Diseases 0.000 claims 10
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 9
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 9
- 206010005003 Bladder cancer Diseases 0.000 claims 6
- 206010014733 Endometrial cancer Diseases 0.000 claims 6
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 6
- 206010018338 Glioma Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 206010033128 Ovarian cancer Diseases 0.000 claims 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 6
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 6
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 6
- 208000029824 high grade glioma Diseases 0.000 claims 6
- 201000011614 malignant glioma Diseases 0.000 claims 6
- 201000001441 melanoma Diseases 0.000 claims 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims 6
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 5
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 3
- 238000012447 xenograft mouse model Methods 0.000 claims 3
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 2
- 238000009175 antibody therapy Methods 0.000 claims 2
- 102000052833 human CSF1R Human genes 0.000 claims 2
- 102000048362 human PDCD1 Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 238000003782 apoptosis assay Methods 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 102200006539 rs121913529 Human genes 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462072035P | 2014-10-29 | 2014-10-29 | |
| US62/072,035 | 2014-10-29 | ||
| US201562157368P | 2015-05-05 | 2015-05-05 | |
| US62/157,368 | 2015-05-05 | ||
| US201562192025P | 2015-07-13 | 2015-07-13 | |
| US62/192,025 | 2015-07-13 | ||
| PCT/US2015/057781 WO2016069727A1 (en) | 2014-10-29 | 2015-10-28 | Combination therapy for cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020121946A Division JP2020186243A (ja) | 2014-10-29 | 2020-07-16 | がんのための併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533912A JP2017533912A (ja) | 2017-11-16 |
| JP2017533912A5 true JP2017533912A5 (enExample) | 2018-12-06 |
| JP6920989B2 JP6920989B2 (ja) | 2021-08-18 |
Family
ID=54695820
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523273A Active JP6920989B2 (ja) | 2014-10-29 | 2015-10-28 | がんのための併用療法 |
| JP2020121946A Pending JP2020186243A (ja) | 2014-10-29 | 2020-07-16 | がんのための併用療法 |
| JP2022207154A Pending JP2023052067A (ja) | 2014-10-29 | 2022-12-23 | がんのための併用療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020121946A Pending JP2020186243A (ja) | 2014-10-29 | 2020-07-16 | がんのための併用療法 |
| JP2022207154A Pending JP2023052067A (ja) | 2014-10-29 | 2022-12-23 | がんのための併用療法 |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US9765147B2 (enExample) |
| EP (2) | EP3835323A1 (enExample) |
| JP (3) | JP6920989B2 (enExample) |
| KR (1) | KR102636539B1 (enExample) |
| CN (1) | CN107567336B (enExample) |
| AU (1) | AU2015339306B2 (enExample) |
| BR (1) | BR112017008914A2 (enExample) |
| CA (1) | CA2963147A1 (enExample) |
| CY (1) | CY1123957T1 (enExample) |
| DK (1) | DK3212670T3 (enExample) |
| EA (1) | EA036261B1 (enExample) |
| ES (1) | ES2851390T3 (enExample) |
| HR (1) | HRP20210440T1 (enExample) |
| HU (1) | HUE054012T2 (enExample) |
| IL (1) | IL251464B2 (enExample) |
| LT (1) | LT3212670T (enExample) |
| MX (1) | MX381046B (enExample) |
| PL (1) | PL3212670T3 (enExample) |
| PT (1) | PT3212670T (enExample) |
| RS (1) | RS61602B1 (enExample) |
| SG (1) | SG11201702723VA (enExample) |
| SI (1) | SI3212670T1 (enExample) |
| SM (1) | SMT202100164T1 (enExample) |
| TW (1) | TWI711463B (enExample) |
| WO (1) | WO2016069727A1 (enExample) |
| ZA (1) | ZA201702382B (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130302322A1 (en) * | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| US9212224B2 (en) | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| ES2746805T3 (es) | 2013-12-12 | 2020-03-06 | Shanghai hengrui pharmaceutical co ltd | Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo |
| ES2716685T3 (es) | 2014-01-24 | 2019-06-14 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo para PD-1 y usos de las mismas |
| DK3099717T3 (da) | 2014-01-31 | 2019-07-01 | Novartis Ag | Antistofmolekyler med tim-3 og anvendelser deraf |
| WO2015119930A1 (en) | 2014-02-04 | 2015-08-13 | Pfizer Inc. | Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer |
| TWI777174B (zh) | 2014-03-14 | 2022-09-11 | 瑞士商諾華公司 | 針對lag-3之抗體分子及其用途 |
| KR20230086809A (ko) * | 2014-06-23 | 2023-06-15 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체 (ｃｓｆ1ｒ)에 결합하는 항체를 이용하여 병태를 치료하는 방법 |
| EP3191126B1 (en) | 2014-09-13 | 2020-05-13 | Novartis AG | Combination therapies of alk inhibitors |
| BR112017008914A2 (pt) | 2014-10-29 | 2018-01-16 | Five Prime Therapeutics, Inc. | método para tratar câncer, composição e uso da composição |
| MX2017007321A (es) * | 2014-12-02 | 2017-08-25 | Celgene Corp | Terapias de combinacion. |
| GB201500319D0 (en) | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| CN112263677A (zh) * | 2015-02-26 | 2021-01-26 | 默克专利股份公司 | 用于治疗癌症的pd-1/pd-l1抑制剂 |
| AU2016233495B2 (en) | 2015-03-13 | 2022-02-24 | Cytomx Therapeutics, Inc | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof |
| CN107709365A (zh) | 2015-04-13 | 2018-02-16 | 戊瑞治疗有限公司 | 癌症组合疗法 |
| ES2861352T3 (es) * | 2015-04-28 | 2021-10-06 | Bristol Myers Squibb Co | Tratamiento del melanoma positivo para PD-L1 utilizando un anticuerpo anti-PD-1 |
| CN113940996A (zh) * | 2015-05-27 | 2022-01-18 | Ucb生物制药私人有限公司 | 用于治疗神经系统疾病的方法 |
| MY193229A (en) | 2015-06-16 | 2022-09-26 | Merck Patent GmbH | Pd-l1 antagonist combination treatments |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| EA201891178A1 (ru) | 2015-12-14 | 2019-01-31 | Макродженикс, Инк. | Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения |
| CN109475634A (zh) | 2016-06-03 | 2019-03-15 | 百时美施贵宝公司 | 用于治疗复发性小细胞肺癌的方法的抗-pd-1抗体 |
| CA3032783C (en) * | 2016-08-05 | 2022-05-31 | Y-Biologics Inc. | Antibody to programmed cell death 1 (pd-1) and use thereof |
| EP3504239B1 (en) | 2016-08-25 | 2024-05-29 | F. Hoffmann-La Roche AG | Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent |
| EP3515495A4 (en) * | 2016-09-26 | 2020-08-26 | Ensemble Group Holdings | CANCER ASSESSMENT AND TREATMENT PROCEDURES IN SUBJECTS WITH DYSREGULATED LYMPHATIC SYSTEMS |
| AU2017339856B2 (en) | 2016-10-06 | 2024-09-05 | Merck Patent Gmbh | Dosing regimen of avelumab for the treatment of cancer |
| US20190292246A1 (en) | 2016-11-03 | 2019-09-26 | Juno Therapeutics, Inc. | Combination therapy of a cell based therapy and a microglia imhibitor |
| WO2018115051A1 (en) | 2016-12-22 | 2018-06-28 | F. Hoffmann-La Roche Ag | Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment |
| PL3431105T3 (pl) * | 2017-03-29 | 2020-11-02 | Shionogi & Co., Ltd. | Kompozycja lecznicza do leczenia raka |
| CA3058944A1 (en) | 2017-04-19 | 2018-10-25 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| BR112020004879A2 (pt) * | 2017-09-13 | 2020-09-15 | Five Prime Therapeutics, Inc. | métodos para tratar o câncer pancreático, para tratar o câncer e para determinar a responsividade de um sujeito com câncer |
| MX2020004756A (es) * | 2017-11-16 | 2020-08-20 | Novartis Ag | Terapias de combinacion. |
| US11046758B2 (en) * | 2017-12-05 | 2021-06-29 | Progastrine Et Cancers S.À R.L. | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer |
| US20200377571A1 (en) * | 2017-12-08 | 2020-12-03 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| WO2019139583A1 (en) * | 2018-01-10 | 2019-07-18 | Lee Patrice A | Methods and combination therapy to treat cancer |
| KR102874471B1 (ko) * | 2018-03-05 | 2025-10-31 | 매사추세츠 아이 앤드 이어 인퍼머리 | 콜로니 자극 인자의 표적화에 의한 녹내장 및 시신경병증 치료법 |
| CN108610422B (zh) * | 2018-03-29 | 2019-05-28 | 中国人民解放军军事科学院军事医学研究院 | 抑制pd-1/pd-l1信号通路的结合分子 |
| KR20200139724A (ko) * | 2018-03-30 | 2020-12-14 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| WO2020027217A1 (ja) * | 2018-07-31 | 2020-02-06 | 国立大学法人北海道大学 | がんの治療及び／又は予防のための医薬 |
| EP3853251A1 (en) * | 2018-09-19 | 2021-07-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy |
| US20220213193A1 (en) | 2019-05-06 | 2022-07-07 | Brown University | Bispecific antibodies against chi3l1 and pd1 with enhanced t cell-mediated cytotoxic effects on tumor cells |
| AU2020282791A1 (en) * | 2019-05-31 | 2021-12-09 | ALX Oncology Inc. | Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor |
| EP4008351A4 (en) * | 2019-08-02 | 2023-08-09 | CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. | Anti-pd-1 antibody and medical use thereof |
| BR112022008817A2 (pt) | 2019-11-27 | 2022-07-26 | Alx Oncology Inc | Terapias combinadas para tratamento de câncer |
| CN114907267A (zh) * | 2021-02-08 | 2022-08-16 | 中国科学院上海药物研究所 | 用于抗肿瘤的药物组合 |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| WO2025129066A1 (en) * | 2023-12-15 | 2025-06-19 | The Regents Of The University Of California | Detection, prevention, and reversal of acquired resistance to immune checkpoint blockade therapy |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0382781B1 (en) | 1987-10-23 | 1993-09-29 | Genetics Institute, Inc. | Composition for treating cancers characterized by over-expression of the c-fms proto-oncogene |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| WO1993025687A1 (en) | 1992-06-09 | 1993-12-23 | Chiron Corporation | Crystallization of m-csf |
| US20020193575A1 (en) | 1993-09-07 | 2002-12-19 | Smithkline Beecham P.L.C. | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
| US6972323B1 (en) | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| WO1999029345A1 (en) | 1997-12-05 | 1999-06-17 | La Jolla Institute For Experimental Medicine | Inhibition of tumor growth by macrophage intervention |
| CA2348292A1 (en) | 1998-10-30 | 2000-05-11 | Takeda Chemical Industries, Ltd. | Betacellulin protein-containing preparation |
| WO2001014557A1 (en) | 1999-08-23 | 2001-03-01 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| ATE240744T1 (de) | 1999-10-28 | 2003-06-15 | Hofbauer Reinhold | Verwendung von csf-1-inhibitoren |
| WO2001034177A2 (en) | 1999-11-08 | 2001-05-17 | The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth & Human Services, The National Institutes Of Health | Method of treating a viral infection using antagonists of macrophage colony stimulating factor |
| US7108852B2 (en) | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
| US7455836B2 (en) | 2000-05-08 | 2008-11-25 | The University Of Melbourne | Method of treatment and agents useful for same |
| US6773895B2 (en) | 2000-09-01 | 2004-08-10 | Boehringer Ingelheim Pharma Kg | Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases |
| US7247618B2 (en) | 2001-04-30 | 2007-07-24 | Tripathi Rajavashisth | Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling |
| CA2450793A1 (en) | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| EP1572106B1 (en) | 2002-11-15 | 2010-05-05 | Novartis Vaccines and Diagnostics, Inc. | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7807389B2 (en) | 2003-03-14 | 2010-10-05 | University Of Rochester | Methods and compositions related to joint inflammation diseases |
| CN1826324B (zh) | 2003-05-22 | 2011-12-07 | 雅培制药有限公司 | 吲唑、苯并异*唑和苯并异噻唑激酶抑制剂 |
| CN101979650B (zh) | 2003-10-22 | 2015-09-16 | 凯克研究生院 | 使用单倍体交配策略在酵母中合成异聚多亚基多肽的方法 |
| GB0325836D0 (en) | 2003-11-05 | 2003-12-10 | Celltech R&D Ltd | Biological products |
| WO2005070447A2 (en) | 2004-01-21 | 2005-08-04 | Chiron Corporation | M-csf muteins and uses thereof |
| CA2565974A1 (en) | 2004-05-14 | 2005-12-01 | Receptor Biologix, Inc. | Cell surface receptor isoforms and methods of identifying and using the same |
| ATE540973T1 (de) | 2004-07-22 | 2012-01-15 | Five Prime Therapeutics Inc | Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung |
| WO2006076288A2 (en) | 2005-01-11 | 2006-07-20 | Five Prime Therapeutics, Inc. | Dna constructs for long-term expression of intravascularly injected naked dna |
| CA2589895A1 (en) | 2005-01-27 | 2006-08-03 | Five Prime Therapeutics, Inc. | Leader sequences for directing secretion of polypeptides and methods for production thereof |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| ES2720160T3 (es) | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| KR20080082628A (ko) | 2005-11-10 | 2008-09-11 | 리셉터 바이오로직스 인크 | 수용체 및 리간드 이소형태의 제조 방법 |
| WO2007075933A2 (en) | 2005-12-21 | 2007-07-05 | Cell Signaling Technology, Inc. | Translocation and mutant csf1r kinase in human leukemia |
| EP1977238B1 (en) | 2005-12-22 | 2016-09-28 | Novartis AG | Soluble human m-csf receptor and uses thereof |
| JP5580535B2 (ja) | 2006-01-05 | 2014-08-27 | ノバルティス アーゲー | 癌転移および癌転移に関連する骨量減少を予防および処置するための方法 |
| CA2669599A1 (en) | 2006-11-17 | 2008-05-22 | Biogen Idec Ma Inc. | Systemic administration of colony stimulating factors to treat amyloid associated disorders |
| DE602008004296D1 (de) | 2007-02-14 | 2011-02-17 | Vaccinex Inc | Humanisierte anti-cd100-antikörper |
| WO2008124858A2 (en) | 2007-04-11 | 2008-10-23 | F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. | Targeted receptor |
| US20100298217A1 (en) | 2007-05-30 | 2010-11-25 | Evan Richard Stanley | Csf-1r mutants |
| JP5191537B2 (ja) | 2007-06-18 | 2013-05-08 | エム・エス・ディー・オス・ベー・フェー | ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体 |
| MX2010001918A (es) | 2007-08-21 | 2010-03-11 | Amgen Inc | Proteinas enlazadas al antigeno humano de celula de cepa mcdonough de felino. |
| US7981415B2 (en) | 2007-09-07 | 2011-07-19 | Cisthera, Inc. | Humanized PAI-1 antibodies |
| AU2008318656A1 (en) | 2007-10-31 | 2009-05-07 | Janssen Pharmaceutica N.V. | Biomarker for assessing response to FMS treatment |
| EP2241333A1 (en) | 2007-12-12 | 2010-10-20 | National Cancer Center | Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| US8470977B2 (en) | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
| CN101970496B (zh) | 2008-03-14 | 2014-04-16 | 特朗斯吉有限公司 | 针对csf-1r的抗体 |
| US20110129456A1 (en) * | 2008-05-05 | 2011-06-02 | Yaolin Wang | Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer |
| EP2307050A4 (en) * | 2008-07-04 | 2012-07-25 | Ono Pharmaceutical Co | USE OF A EFFECTIVENESS MARKER TO OPTIMIZE THE THERAPEUTIC EFFECTIVENESS OF AN ANTI-HUMAN PD-1 ANTIBODY ON CANCERS |
| RS54233B1 (sr) | 2008-08-25 | 2015-12-31 | Amplimmune Inc. | Kompozicije pd-1 antagonista i postupci za njihovu primenu |
| US8080246B2 (en) | 2008-11-26 | 2011-12-20 | Five Prime Therapeutics, Inc. | Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules |
| WO2010062401A2 (en) | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules |
| HUE065752T2 (hu) | 2008-12-09 | 2024-06-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére |
| AU2010329934B2 (en) | 2009-12-10 | 2015-05-14 | F. Hoffmann-La Roche Ag | Antibodies binding preferentially human CSF1R extracellular domain 4 and their use |
| CA2789071C (en) | 2010-03-05 | 2018-03-27 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
| MX2012010014A (es) | 2010-03-05 | 2012-09-21 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| AR080698A1 (es) | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
| MX355418B (es) | 2010-05-04 | 2018-04-18 | Five Prime Therapeutics Inc | Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r). |
| CN107090029B (zh) * | 2010-11-11 | 2021-07-13 | 港大科桥有限公司 | 可溶性 pd-1变体、融合构建体及其用途 |
| AR084234A1 (es) | 2010-12-13 | 2013-05-02 | Novartis Ag | Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17) |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| HK1200032A1 (en) | 2011-10-21 | 2015-07-31 | Transgene Sa | Modulation of macrophage activation |
| US20140288279A1 (en) | 2011-10-21 | 2014-09-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | M-DC8+ Monocyte Depleting Agent for the Prevention or the Treatment of a Condition Associated with a Chronic Hyperactivation of the Immune System |
| AR090263A1 (es) * | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| JP2015517490A (ja) | 2012-05-11 | 2015-06-22 | ファイブ プライム セラピューティックス インコーポレイテッド | コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法 |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| US9212224B2 (en) | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
| SG10201906328RA (en) | 2012-08-31 | 2019-08-27 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| BR112017008914A2 (pt) | 2014-10-29 | 2018-01-16 | Five Prime Therapeutics, Inc. | método para tratar câncer, composição e uso da composição |
| MA40737A (fr) | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
| JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
| IL265759B2 (en) | 2016-10-06 | 2025-10-01 | Genentech Inc | Therapeutic and diagnostic methods for cancer |
| CN111492245A (zh) | 2017-07-21 | 2020-08-04 | 基因泰克公司 | 癌症的治疗和诊断方法 |
-
2015
- 2015-10-28 BR BR112017008914A patent/BR112017008914A2/pt not_active Application Discontinuation
- 2015-10-28 CN CN201580071491.1A patent/CN107567336B/zh active Active
- 2015-10-28 PT PT157982646T patent/PT3212670T/pt unknown
- 2015-10-28 PL PL15798264T patent/PL3212670T3/pl unknown
- 2015-10-28 SI SI201531496T patent/SI3212670T1/sl unknown
- 2015-10-28 US US14/925,534 patent/US9765147B2/en active Active
- 2015-10-28 EP EP20207287.2A patent/EP3835323A1/en not_active Withdrawn
- 2015-10-28 SM SM20210164T patent/SMT202100164T1/it unknown
- 2015-10-28 CA CA2963147A patent/CA2963147A1/en active Pending
- 2015-10-28 SG SG11201702723VA patent/SG11201702723VA/en unknown
- 2015-10-28 KR KR1020177014031A patent/KR102636539B1/ko active Active
- 2015-10-28 EA EA201790926A patent/EA036261B1/ru not_active IP Right Cessation
- 2015-10-28 JP JP2017523273A patent/JP6920989B2/ja active Active
- 2015-10-28 EP EP15798264.6A patent/EP3212670B1/en active Active
- 2015-10-28 TW TW104135474A patent/TWI711463B/zh not_active IP Right Cessation
- 2015-10-28 RS RS20210347A patent/RS61602B1/sr unknown
- 2015-10-28 WO PCT/US2015/057781 patent/WO2016069727A1/en not_active Ceased
- 2015-10-28 LT LTEP15798264.6T patent/LT3212670T/lt unknown
- 2015-10-28 MX MX2017005553A patent/MX381046B/es unknown
- 2015-10-28 ES ES15798264T patent/ES2851390T3/es active Active
- 2015-10-28 HR HRP20210440TT patent/HRP20210440T1/hr unknown
- 2015-10-28 HU HUE15798264A patent/HUE054012T2/hu unknown
- 2015-10-28 DK DK15798264.6T patent/DK3212670T3/da active
- 2015-10-28 AU AU2015339306A patent/AU2015339306B2/en not_active Ceased
- 2015-10-28 IL IL251464A patent/IL251464B2/en unknown
-
2017
- 2017-04-04 ZA ZA2017/02382A patent/ZA201702382B/en unknown
- 2017-08-18 US US15/680,664 patent/US10221244B2/en active Active
-
2019
- 2019-01-09 US US16/243,510 patent/US10618967B2/en active Active
-
2020
- 2020-03-04 US US16/808,910 patent/US11566076B2/en active Active
- 2020-07-16 JP JP2020121946A patent/JP2020186243A/ja active Pending
-
2021
- 2021-03-17 CY CY20211100224T patent/CY1123957T1/el unknown
-
2022
- 2022-12-21 US US18/069,511 patent/US20230212299A1/en not_active Abandoned
- 2022-12-23 JP JP2022207154A patent/JP2023052067A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533912A5 (enExample) | ||
| RU2017133273A (ru) | Ингибиторы pd-1 / pd-l1 для лечения рака | |
| JP2018070648A5 (enExample) | ||
| ES2749098T3 (es) | Anticuerpos ANTI-B7-H1 y ANTI-CTLA-4 para tratar el cáncer de pulmón no microcítico | |
| CN110536905B (zh) | 用于治疗肺癌的抗pd-1抗体 | |
| JP2018508512A5 (enExample) | ||
| RU2018101314A (ru) | Комбинированные способы лечения антагонистами pd-l1 | |
| JP2019519499A5 (enExample) | ||
| JP2018518454A5 (enExample) | ||
| JP2015532292A5 (enExample) | ||
| JP2019506403A5 (enExample) | ||
| JP2020508317A5 (enExample) | ||
| HRP20210440T1 (hr) | Kombinirana terapija za rak | |
| RU2019106663A (ru) | Комбинированная терапия рака | |
| JP2017501167A5 (enExample) | ||
| HRP20220399T1 (hr) | Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost | |
| JP2016520082A5 (enExample) | ||
| CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| HRP20171758T1 (hr) | Kombinacija dr5 agonista i anti-pd-1 antagonista i načini primjene | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| RU2018111529A (ru) | Комбинированная терапия для лечения рака | |
| RU2019133787A (ru) | Комбинация анти-pd-l1 антитела и ингибитора днк-пк для лечения злокачественного новообразования | |
| JP2017536408A5 (enExample) | ||
| WO2016090024A4 (en) | Combination therapy for treatment of cancer | |
| CN108079292A (zh) | 一种抗pd-1抗体在制备治疗肝癌的药物中的用途 |